Insider Selling: Vericel (NASDAQ:VCEL) Insider Sells 1,500 Shares of Company Stock

Posted by Francis Steltz on Nov 6th, 2026

Vericel Corporation (NASDAQ:VCEL – Get Free Report) insider Jonathan Siegal sold 1,500 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $52.90, for a total value of $79,350.00. Following the sale, the insider owned 1,259 shares of the company’s stock, valued at approximately $66,601.10. The trade was a 54.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Vericel Stock Up 5.5%

Shares of VCEL traded up $2.84 during trading hours on Friday, hitting $54.62. 1,612,332 shares of the company were exchanged, compared to its average volume of 598,922. Vericel Corporation has a fifty-two week low of $28.95 and a fifty-two week high of $55.60. The company has a market cap of $2.80 billion, a price-to-earnings ratio of 116.22 and a beta of 1.08. The firm’s fifty day moving average is $40.74 and its 200 day moving average is $38.80.

Vericel (NASDAQ:VCEL – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.21. The business had revenue of $85.37 million during the quarter, compared to analysts’ expectations of $77.95 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. Vericel’s revenue was up 26.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 earnings per share. Analysts anticipate that Vericel Corporation will post 0.54 EPS for the current year.

Institutional Trading of Vericel

Several institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in Vericel by 17.7% during the second quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company’s stock valued at $84,000 after acquiring an additional 283 shares during the last quarter. Kopp Family Office LLC raised its position in shares of Vericel by 0.6% in the 3rd quarter. Kopp Family Office LLC now owns 51,352 shares of the biotechnology company’s stock worth $2,061,000 after acquiring an additional 299 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Vericel by 0.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 157,081 shares of the biotechnology company’s stock valued at $6,195,000 after purchasing an additional 435 shares during the period. Handelsbanken Fonder AB lifted its stake in shares of Vericel by 2.2% in the 2nd quarter. Handelsbanken Fonder AB now owns 23,079 shares of the biotechnology company’s stock valued at $1,027,000 after purchasing an additional 500 shares during the period. Finally, Gagnon Securities LLC boosted its position in shares of Vericel by 7.3% during the 3rd quarter. Gagnon Securities LLC now owns 7,839 shares of the biotechnology company’s stock valued at $315,000 after purchasing an additional 536 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts have weighed in on VCEL shares. TD Cowen upped their target price on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Truist Financial set a $65.00 price target on Vericel in a research note on Friday. HC Wainwright boosted their price target on Vericel from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Vericel in a research report on Thursday, October 29th. Finally, Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Four research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Vericel has an average rating of “Moderate Buy” and an average target price of $60.80.

Read Our Latest Stock Report on Vericel

More Vericel News

Here are the key news stories impacting Vericel this week:

Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, while earnings were $0.27 per share—well above analyst estimates. Net income increased 179% to $14.2 million; the company also cited record MACI sales. Vericel Q3 2026 results and guidance
Positive Sentiment: Vericel raised its 2026 revenue guidance to $344–$346 million, above the approximately $336 million consensus, and increased its adjusted EBITDA margin guidance to 28%. Vericel Q3 2026 results and guidance
Positive Sentiment: HC Wainwright raised its price target from $72 to $75 and reaffirmed a Buy rating, signaling continued analyst confidence after the results. HC Wainwright raises Vericel price target
Negative Sentiment: A separate analysis described VCEL as potentially overvalued relative to its earnings support, a risk if future growth does not justify investor expectations. Analysis of Vericel’s valuation

Vericel Company Profile

(Get Free Report)

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.